{"id":"https://openalex.org/W96048289","doi":null,"title":"FLAP inhibitors for the treatment of inflammatory diseases.","display_name":"FLAP inhibitors for the treatment of inflammatory diseases.","publication_year":2009,"publication_date":"2009-11-01","ids":{"openalex":"https://openalex.org/W96048289","mag":"96048289","pmid":"https://pubmed.ncbi.nlm.nih.gov/19876784"},"language":"en","primary_location":{"id":"pmid:19876784","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19876784","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5074951041","display_name":"Anthony Peter Sampson","orcid":"https://orcid.org/0009-0008-9653-8935","observed_orcids":["https://orcid.org/0009-0008-9653-8935"]},"institutions":[{"id":"https://openalex.org/I2801388914","display_name":"Southampton General Hospital","ror":"https://ror.org/011cztj49","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801388914","https://openalex.org/I2802965805"]},{"id":"https://openalex.org/I43439940","display_name":"University of Southampton","ror":"https://ror.org/01ryk1543","country_code":"GB","type":"education","lineage":["https://openalex.org/I43439940"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Anthony P Sampson","raw_affiliation_strings":["University of Southampton, III Division, The Sir Henry Wellcome Building, Mailpoint 825, Level F, South Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK. A.P.Sampson@southampton.ac.uk"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Southampton, III Division, The Sir Henry Wellcome Building, Mailpoint 825, Level F, South Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK. A.P.Sampson@southampton.ac.uk","institution_ids":["https://openalex.org/I2801388914","https://openalex.org/I43439940"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5074951041"],"corresponding_institution_ids":["https://openalex.org/I2801388914","https://openalex.org/I43439940"],"apc_list":null,"apc_paid":null,"fwci":3.2664,"has_fulltext":false,"cited_by_count":46,"citation_normalized_percentile":{"value":0.90428094,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"10","issue":"11","first_page":"1163","last_page":"72"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.6259999871253967,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.6259999871253967,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12910","display_name":"Eicosanoids and Hypertension Pharmacology","score":0.24369999766349792,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.0892999991774559,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/flap-inhibitors","display_name":"FLAP inhibitors","score":0.8309999704360962},{"id":"https://openalex.org/keywords/leukotriene-biosynthesis","display_name":"leukotriene biosynthesis","score":0.8700000047683716},{"id":"https://openalex.org/keywords/5-lipoxygenase-activating-protein","display_name":"5-lipoxygenase-activating protein","score":0.9419999718666077},{"id":"https://openalex.org/keywords/leukotriene-b4","display_name":"leukotriene B4","score":0.8489999771118164},{"id":"https://openalex.org/keywords/cysteinyl-leukotrienes","display_name":"cysteinyl leukotrienes","score":0.9919999837875366},{"id":"https://openalex.org/keywords/asthma","display_name":"asthma","score":0.7950000166893005},{"id":"https://openalex.org/keywords/inflammatory-diseases","display_name":"inflammatory diseases","score":0.7039999961853027},{"id":"https://openalex.org/keywords/mk-886","display_name":"MK-886","score":0.9160000085830688},{"id":"https://openalex.org/keywords/leukotriene-receptor-antagonists","display_name":"leukotriene receptor antagonists","score":0.824999988079071}],"concepts":[{"id":"https://openalex.org/C2776452501","wikidata":"https://www.wikidata.org/wiki/Q424190","display_name":"Leukotriene","level":3,"score":0.6549134850502014},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.589947521686554},{"id":"https://openalex.org/C2776352991","wikidata":"https://www.wikidata.org/wiki/Q407680","display_name":"Eicosanoid","level":4,"score":0.4991481304168701},{"id":"https://openalex.org/C2779543280","wikidata":"https://www.wikidata.org/wiki/Q2704310","display_name":"Leukotriene C4","level":4,"score":0.4986741542816162},{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.4951993525028229},{"id":"https://openalex.org/C2777242621","wikidata":"https://www.wikidata.org/wiki/Q647917","display_name":"Leukotriene D4","level":4,"score":0.473786324262619},{"id":"https://openalex.org/C90342290","wikidata":"https://www.wikidata.org/wiki/Q94234745","display_name":"Arachidonate 5-lipoxygenase","level":4,"score":0.47001269459724426},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4474397897720337},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.43030911684036255},{"id":"https://openalex.org/C180899940","wikidata":"https://www.wikidata.org/wiki/Q117982","display_name":"Lipid signaling","level":3,"score":0.42738503217697144},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.417820006608963},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4135287404060364},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3826083540916443},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.28335726261138916},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.15106141567230225},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12606438994407654},{"id":"https://openalex.org/C2778078955","wikidata":"https://www.wikidata.org/wiki/Q407699","display_name":"Arachidonic acid","level":3,"score":0.06685003638267517}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002352","descriptor_name":"Carrier Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D008565","descriptor_name":"Membrane Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015289","descriptor_name":"Leukotrienes","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D016859","descriptor_name":"Lipoxygenase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058927","descriptor_name":"5-Lipoxygenase-Activating Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"pmid:19876784","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19876784","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},{"id":"pmh:oai:eprints.soton.ac.uk:73113","doi":null,"is_oa":false,"landing_page_url":"http://www.ncbi.nlm.nih.gov/pubmed/19876784>)","pdf_url":null,"source":{"id":"https://openalex.org/S4306401019","display_name":"ePrints Soton (University of Southampton)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I43439940","host_organization_name":"University of Southampton","host_organization_lineage":["https://openalex.org/I43439940"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Article"},{"id":"mag:96048289","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19876784","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9789000153541565,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2734973925","https://openalex.org/W1971572251","https://openalex.org/W73825595","https://openalex.org/W1968869744","https://openalex.org/W2096096368","https://openalex.org/W2529025668","https://openalex.org/W2140887919","https://openalex.org/W1968575019","https://openalex.org/W4229706191","https://openalex.org/W2417281944"],"abstract_inverted_index":{"Leukotrienes":[0],"are":[1,6],"lipid":[2],"inflammatory":[3,100,160],"mediators":[4],"that":[5,73],"implicated":[7],"in":[8,36,94,102],"asthma,":[9],"COPD,":[10],"arthritis,":[11],"cardiovascular":[12],"disease":[13],"and":[14,56,64,88,136,143],"cancer.":[15],"Leukotriene":[16],"synthesis":[17],"requires":[18],"5-lipoxygenase":[19],"activating":[20],"protein":[21,28],"(FLAP),":[22],"which":[23],"acts":[24],"as":[25,69,85],"a":[26,76],"scaffolding":[27],"for":[29,156],"the":[30,37,43,50,57,103,109,126,157],"assembly":[31],"of":[32,46,52,79,112,125,129,159],"other":[33],"enzymes":[34],"involved":[35],"leukotriene":[38,54],"synthetic":[39],"pathway":[40],"occurring":[41],"at":[42],"nuclear":[44],"envelope":[45],"leukocytes.":[47],"By":[48],"blocking":[49],"formation":[51],"both":[53],"B4":[55],"cysteinyl":[58],"leukotrienes":[59],"(ie,":[60],"LTC4":[61],",":[62],"LTD4":[63],"LTE4),":[65],"FLAP":[66,82,130,138],"inhibitors":[67,83,139],"act":[68],"broad-spectrum":[70],"leukotriene-modifier":[71],"drugs":[72],"may":[74],"have":[75,151],"wide":[77],"range":[78],"therapeutic":[80],"applications.":[81],"such":[84],"MK-886,":[86],"MK-0591":[87],"veliflapon":[89],"(BAY-X-1005,":[90],"DG-031)":[91],"demonstrated":[92],"promise":[93],"clinical":[95],"trials":[96,155],"with":[97,99],"patients":[98],"diseases":[101],"mid":[104],"1990":[105],"s,":[106],"but,":[107],"unlike":[108],"'lukast'":[110],"class":[111],"cysteinyl-leukotriene":[113],"receptor":[114],"antagonists,":[115],"these":[116],"compounds":[117],"were":[118],"not":[119],"brought":[120],"to":[121],"market.":[122],"The":[123],"elucidation":[124],"3D":[127],"structure":[128],"has":[131],"enabled":[132],"novel":[133],"compound":[134],"development,":[135],"several":[137],"including":[140,162],"2190914":[141],"(AM-103)":[142],"GSK-2190915":[144],"(both":[145],"under":[146],"development":[147],"by":[148],"GlaxoSmithKline":[149],"plc)":[150],"entered":[152],"phase":[153],"II":[154],"treatment":[158],"disease,":[161],"asthma.":[163]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}